Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy  Misghina Weldegiorgis, Dick de Zeeuw, Liang Li, Hans-Henrik Parving, Fan Fan Hou, Giuseppe Remuzzi, Tom Greene, Hiddo J.L. Heerspink  American Journal of Kidney Diseases  Volume 71, Issue 1, Pages 91-101 (January 2018) DOI: 10.1053/j.ajkd.2017.08.010 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Examples of observed trajectories with increasing probability (Prob) of nonlinearity to indicate the increasing oscillation with increasing probability of nonlinearity. The graphs in the left 2 columns correspond to the largest group of individuals in each trial (all with low probability of nonlinearity). For illustration purposes, individuals with a probability of nonlinearity of ∼0.5 and ∼0.9 were also selected. Dots represent single glomerular filtration rate (GFR) estimates (eGFRs) and the smooth curve represents estimated trajectory. The band is the 95% Bayesian confidence interval. The vertical dotted lines mark the observed time of either end-stage renal disease, death, or censoring. Abbreviations: BENEDICT, Bergamo Nephrologic Diabetes Complications Trial; ESBARI, Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency; IDNT, Irbesartan Type II Diabetic Nephropathy Trial; REIN, Ramipril Efficacy In Nephropathy; RENAAL, Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan; ROAD, Renoprotection of Optimal Antiproteinuric Doses. American Journal of Kidney Diseases 2018 71, 91-101DOI: (10.1053/j.ajkd.2017.08.010) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Distribution of probability of nonlinearity in 6 clinical trials. The histograms indicate the distribution of probability of nonlinearity plotted to the scale of the left vertical axis. The curved line indicates the percentage of patients with higher probability of nonlinearity plotted to the scale of the right vertical axis. Abbreviations: BENEDICT, Bergamo Nephrologic Diabetes Complications Trial; ESBARI, Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency; IDNT, Irbesartan Type II Diabetic Nephropathy Trial; REIN, Ramipril Efficacy In Nephropathy; RENAAL, Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan; ROAD, Renoprotection of Optimal Antiproteinuric Doses. American Journal of Kidney Diseases 2018 71, 91-101DOI: (10.1053/j.ajkd.2017.08.010) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions